Pharma Exec for Maker of $150,000 Cancer Drug Tells Investors Its Pricing Is “Very Responsible” Posted on December 30, 2015November 10, 2019Author theinterceptPosted in The InterceptLeave a Reply Favorite A top official at pharmaceutical giant Johnson & Johnson dismissed questions on a recenYou must subscribe and be logged in to read this archived content.visit original source at firstlook.org/theintercept/
